Earnings & Valuation
This table compares SQZ Biotechnologies and Organovo”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SQZ Biotechnologies | $18.16 million | 0.05 | -$79.46 million | ($2.61) | -0.01 |
Organovo | $122,000.00 | 0.00 | -$14.67 million | ($10.20) | N/A |
Organovo has lower revenue, but higher earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
Risk and Volatility
SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Profitability
This table compares SQZ Biotechnologies and Organovo’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
Organovo | -10,151.64% | -346.26% | -187.53% |
Summary
SQZ Biotechnologies beats Organovo on 9 of the 10 factors compared between the two stocks.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About Organovo
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.